PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25116336-0	2014	Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.	Arsenic Trioxide	0-16	tumor protein p53	Homo sapiens	72-75	
25116336-4	2014	Previously, we found that arsenic trioxide (ATO), a drug for acute promyelocytic leukemia, degrades mutant p53 protein through a proteasome pathway.	Arsenic Trioxide	26-42	tumor protein p53	Homo sapiens	107-110	
25116336-4	2014	Previously, we found that arsenic trioxide (ATO), a drug for acute promyelocytic leukemia, degrades mutant p53 protein through a proteasome pathway.	Arsenic Trioxide	44-47	tumor protein p53	Homo sapiens	107-110	
25116336-8	2014	We also found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, ATO-induced degradation of mutant p53 protein.	Arsenic Trioxide	94-97	tumor protein p53	Homo sapiens	128-131	
25116336-10	2014	Interestingly, we found that ATO cooperates with HSP90 or HDAC inhibitor to promote mutant p53 degradation and growth suppression in tumor cells.	Arsenic Trioxide	29-32	tumor protein p53	Homo sapiens	91-94	
25116336-11	2014	Together, these data suggest that ATO promotes mutant p53 degradation in part via induction of the Pirh2-dependent proteasome pathway.	Arsenic Trioxide	34-37	tumor protein p53	Homo sapiens	54-57